ABSTRACT
Background Alternating hemiplegia of childhood (AHC) is a rare disorder with both neurologic and cardiac manifestations. The ATP1A3-D801N variant is associated with a pathologically short QT interval and risk of ventricular arrhythmia following bradycardia; however, the mechanism of this remains unknown. We investigated the relationship between heart rate (HR), QT, and QTc, hypothesizing that individuals with ATP1A3-D801N have abnormal, impaired shortening of QT and QTc at lower HR leading to arrhythmia predisposition.
Methods We performed a retrospective observational study of individuals who underwent clinical evaluation, Holter monitoring, and genetic testing for AHC at Duke University Hospitals. We also compiled a group of healthy individuals as a control cohort. A larger, worldwide cohort of individuals with ATP1A3-related phenotypes was compiled to investigate sinus node dysfunction. Linear regression analysis was then performed.
Results The cohort consisted of 44 individuals with ATP1A3-related phenotypes with 81 Holter recordings (52.27% female; mean age at first Holter 8.04 years, range 0.58 – 33 years), compared to 36 healthy individuals with 57 Holter recordings (52.78% female; mean age at first Holter 9.84 years, range 0.08 – 38 years). Individuals with ATP1A3-D801N had reduced prolongation of QT at lower HR, manifest as a significantly lower slope for HR vs QT compared to healthy (P<0.0001). This resulted in a significantly higher slope of the relationship for HR vs QTc compared to healthy (P<0.0001). Individuals with ATP1A3-related phenotypes and baseline QTc <350 milliseconds (ms) had increased shortening of QT and QTc at lower HR compared to those with normal QTc (P=0.003; P=0.001). Among worldwide cases, 3 out of 131 individuals with ATP1A3-related phenotypes required device implantation and/or had sinus pauses >4 seconds.
Conclusions Individuals with the ATP1A3-D801N variant exhibit paradoxical shortening of QT and QTc at lower HR, which contributes to an increased risk of arrhythmias during bradycardia. This is exacerbated by an underlying risk of sinus node dysfunction.
Clinical Perspective What is Known:
Individuals with ATP1A3-D801N have a short baseline QTc.
Two individuals with AHC experienced ventricular fibrillation following bradycardia.
What the Study Adds:
The QT and QTc shorten to a greater extent at lower heart rate in individuals with ATP1A3-D801N than in healthy individuals.
Individuals with ATP1A3-related phenotypes and QTc <350ms show greater impairment of QT and QTc dynamics than those with normal QTc.
There is low prevalence of device implantation and significant sinus pauses in individuals with ATP1A3-related phenotypes, with a relatively greater prevalence in those with ATP1A3-D801N.
Competing Interest Statement
MAM has intellectual property interest in gene therapy for ATP1A3 related disease pending patent application.
Funding Statement
MKB is supported by The Paul Gillette PACES Research Grant and by National Institute of Health (NIH) T32 GM007171. APL is supported by National Institutes of Health (R01-HL160654, R01-HL166217), Doris Duke Charitable Foundation (CSDA-2020098), John Taylor Babbitt Foundation, The Hartwell Foundation, Additional Ventures, Y.T. and Alice Chen Pediatric Genetics and Genomics Research Center.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This was a retrospective study approved by the Duke University Hospitals Institutional Review Board, IRB #Pro00094341. Informed consent was waived. In addition, retrospective data on AHC patients was obtained using the International Consortium for Research on AHC and all the ATP1A3 Rare Diseases (IAHCRC), according to the rules of the IAHCRC Charter. All sites had ethics board or IRB approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Added additional validation studies including manual measurements using diagnostic ECGs and determined the impact of medications on QT response to heart rate changes
Data Availability
Dr. Andrew Landstrom had full access to all the data in the study and takes responsibility for data integrity and accuracy of data analysis.
Non-Standard Abbreviations and Acronyms
- AHC
- alternating hemiplegia of childhood
- ATP1A3
- gene encoding for the alpha-3 subunit of sodium-potassium ATPase
- ATP1A3-D801N
- D801N missense variant in ATP1A3-encoded ATP1A3
- ATP1A3 Non-D801N
- missense single nucleotide variants, not including D801N, in ATP1A3-encoded ATP1A3
- ATP1A3 LOF
- presumed loss of function variants in ATP1A3-encoded ATP1A
- ATP1A3 Neg
- no pathogenic or likely pathogenic variant identified in ATP1A3
- QTc
- corrected QT interval
- HR
- heart rate
- BPM
- beats per minute
- SUDEP
- sudden unexplained death in epilepsy
